<DOC>
	<DOCNO>NCT00761280</DOCNO>
	<brief_summary>In multinational Phase III study efficacy safety 10 µM AP 12009 compare standard chemotherapy ( temozolomide BCNU CCNU ) adult patient confirm recurrent refractory anaplastic astrocytoma ( WHO grade III ) secondary glioblastoma ( WHO grade IV ) .</brief_summary>
	<brief_title>Efficacy Safety AP 12009 Patients With Recurrent Refractory Anaplastic Astrocytoma Secondary Glioblastoma</brief_title>
	<detailed_description>The purpose study compare safety efficacy 10 µM concentration AP 12009 standard chemotherapy ( temozolomide , BCNU , CCNU ) adult patient recurrent refractory anaplastic astrocytoma ( AA , WHO grade III ) secondary glioblastoma ( GBM , WHO grade IV ) . AP 12009 ( trabedersen ) phosphorothioate antisense oligodeoxynucleotide specific mRNA human Transforming Growth Factor beta 2 ( TGF-beta-2 ) , apply intratumorally . The growth factor TGF-beta play key role malignant progression various tumor induce proliferation , invasion , metastasis , angiogenesis , escape immunosurveillance . In patient high-grade glioma , TGF-beta-2 overexpression associate disease stage , clinical prognosis , immunodeficient state patient . Main objective study determine survival ( rate ) tumor response . Important note : Due early trial termination , result limited data availability , analyse remain descriptive nature , . No conclusive endpoint analysis perform .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Trabedersen</mesh_term>
	<criteria>The patient provide write informed consent prior studyrelated procedure . The patient least 18 year age equal 70 year . The patient present diagnosis AA secondary GBM . The patient measurable lesion ( &gt; 1 ccm volume , central MRI review ) . The lesion ( sum lesion ) exceed 50 ccm volume ( central MRI review ) . The tumor localize supratentorially ( central MRI review ) . All patient recurrent refractory disease , i.e . disease progress prior surgery radiotherapy time disease course stage . Secondary GBM patient progress previous diagnosis A and/or AA . The patient receive one chemotherapy regimen . Radiation concomitant chemotherapy , follow adjuvant chemotherapy , consider one chemotherapy regimen . The patient eligible chemotherapy . The patient maximum dose 4 mg/day dexamethasone equivalent dos corticosteroid , stable decrease least 3 week prior Screening . The patient male nonpregnant , nonlactating female . Females childbearing potential must negative betaHCG pregnancy test Screening . Females childbearing potential male must practice strict birth control . The patient must recover acute toxicity cause previous therapy . The patient life expectancy least 3 month . The patient Karnofsky Performance Status least 70 % . The patient show adequate organ function assess follow screen laboratory value : 1 . Adequate renal function determine serum creatinine urea &lt; 2 time upper limit normal 2 . Adequate liver function ALT , AST AP &lt; 3 time upper limit normal , bilirubin &lt; 2.5 mg/dL 3 . INR &lt; 1.5 aPTT &lt; 1.5 x ULN 4 . Hemoglobin &gt; 9 g/dL 5 . Platelet count &gt; 100 x 10E9/L 6 . WBC &gt; 3 x 10E9/L 7 . ANC &gt; 1.5 x 10E9/L ( WBC &gt; 3.0 x 10E9/L ) Patient unable willing comply protocol regulation . The investigator deem necessary surgically ( ) resect present tumor ( NOTE : patient might still eligible randomization later timepoint ) . Tumor surgery , tumor debulking , neurosurgery within 3 month prior randomization . If ≤48hour routine postsurgery MRI ( accordance study specification ) qualify patient study participation , patient randomize 30 ± 7 day postsurgery . Radiotherapy stereotactic ( gamma knife ) radiosurgery within 3 month prior randomization . Prior interstitial brachytherapy brain permanent implant . Prior interstitial brachytherapy brain removable implant within 3 month prior randomization . Chemotherapy , hormone therapy , therapy establish suggest antitumor effect within 4 week ( nitrosoureas : 6 week ) prior randomization . Prior antiTGFbeta 2 targeted therapy . Screening MRI show mass effect cause tumor define significant compression ventricular system and/or midline shift ( ≥ 3 mm , central MRI review ) . Compression ventricular system and/or midline shift ≥ 3 mm due presence ( ) cyst ( ) scar process exclude individual study . Participation another clinical study another investigational medicinal product within 30 day prior randomization . History second independent malignant disorder within 5 year , except carcinoma situ cervix basal cell carcinoma . Presence poorly control seizure . Clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure , unstable angina , poorly control arrhythmia . Myocardial infarction within 6 month prior randomization . Known HIV , HBV HCV infection . Acute viral , bacterial , fungal infection . Acute medical problem may consider become unacceptable risk , condition , might contraindication start study treatment . Presence high risk pulmonary toxicity , define : 1 . Lung function : vital capacity ≤ 70 % 2 . Status follow sequential concomitant thoracic irradiation 3 . Increased risk pulmonary toxicity induce BCNU ( Carmustine ) CCNU ( Lomustine ) . Risk factor include smoking , presence respiratory condition , preexist radiographic pulmonary abnormality , exposure agent cause lung damage . History allergies reagent use study , history celiac disease . Drug abuse extensive use alcohol . Clinically relevant psychiatric disorder / legal incapacity limited legal capacity . Concomitant treatment yellow fever vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Antisense</keyword>
	<keyword>Cancer</keyword>
	<keyword>Transforming Growth Factor beta 2</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Glioma</keyword>
	<keyword>Central Nervous System ( CNS )</keyword>
	<keyword>Convection Enhanced Delivery ( CED )</keyword>
	<keyword>Intratumoral administration</keyword>
</DOC>